1-877-273-4498
Call Now for Expert Advice
 
In This Section
 
  Free Mesothelioma Information Guide
 

Instant Download

More Details »

 

Please fill the form below:

First *
Last *
Email
Phone *
Address
City
State
Zip Code


You Are Here: Mesothelioma Treatment » Treatment Options » Clinical Trials
 

Clinical Trials for Mesothelioma

Clinical Trials - Overview

Clinical trials are a potential option to consider when deciding upon your mesothelioma treatment plan. These trials are new and/or experimental patient treatment plans that show promise but are not part of the mainstream medical treatment options. Only patients believed to receive benefit from a clinical trial are typically accepted.

Each clinical trial works to find better ways to treat, diagnose, screen and monitor diseases, such as mesothelioma, through research and testing.  These trials are sponsored by various groups and agencies including:

  • National Cancer Institute (NCI)
  • National Institutes of Health (NIH)
  • Department of Defense
  • Department of Veterans Affairs
  • Pharmaceutical companies
  • Medical institutions

The National Institutes of Health (NIH) exclusively performs clinical trials. They do not perform routine medical procedures like other medical facilities. Admission is determined by the staff physicians and is only applied to those who meet strict criteria, including having an illness that is presently being researched via clinical study. For more information on the types of trials and admission information, see the NIH Fact Sheet.

The NCI sponsors many clinical trials and makes them widely available in the United States. These include:

  • The Cancer Centers Program – supports research-oriented institutions
  • The Specialized Programs of Research Excellence (SPOREs) – brings scientists and researchers together to design and implement research programs
  • The Clinical Trials Cooperative Group Program – builds cooperative groups of researchers, cancer centers and doctors to identify questions in cancer research and conduct clinical trials.
  • The Cancer Trials Support Unit (CTSU) – allows for NCI phase III trials to be made available to doctors in the United States and Canada.
  • The Community Clinical Oncology Program (CCOP) – clinical trials are made available to a large number of communities across the United States.
  • The National Institutes of Health Clinical Center – a research hospital in Bethesda, Maryland that is part of the NIH.

Each clinical trial has specific criteria that must be met for a patient to be accepted. Each trial must have three phases to be accepted by the Food and Drug Administration. As with any treatment for mesothelioma, it is important to get an early diagnosis and consult with your physicians to make the best decision for your ongoing treatment and care.

Clinical Trial Phases

There are three phases of clinical trials that must be studied before the Food and Drug Administration (FDA) will approve it for use.

  • Phase I – to find the most effective means to administer a new treatment, including the appropriate amount. Teams administering new drugs and treatments watch carefully for any side effects since human testing begins during Phase I.
  • Phase II - the studies are to determine if the drug works. Patients are administered the highest dose that can be safely given based on the information from Phase I.
  • Phase III – this is the largest phase, typically involving hundreds of people. In this phase a control group receives a more widely accepted treatment while a second group receives the new treatment. These groups are carefully watched for side effects. If one group shows significant improvement over the other, or if side effects of the new treatments are too severe, the study is stopped.

There are also different types of clinical trials. These include:

  • Prevention trials which test new approaches that doctors believe may lower the risk of developing a certain cancer. These are typically conducted on healthy individuals with no cancer, or those who have had cancer previously but show no signs.
  • Screening trials study detection methods in an attempt to detect cancer earlier. They focus on finding cancer before it causes symptoms to determine if this early detection will decrease the chance of dying. These trials are conducted on people who do not have any cancer symptoms.
  • Diagnostic trials study processes that could potentially be used to more accurately identify cancer. These trials are conducted on people who have signs or symptoms of cancer.
  • Treatment trials are designed to answer specific questions and evaluate the effectiveness of a new treatment or new way of using a standard treatment. These trials are conducted on people who have cancer.

If you are accepted to a clinical trial for mesothelioma, you have a team of experts closely monitoring your progress. However, there are risks since no one knows the outcome of the new treatment. Only you can decide if a clinical trial is best for you.


List of Cancer & Mesothelioma Clinical Trials

The National Cancer Institute provides a searchable list of clinical trials on their site.  Below is a list of trials and phases for your convenience.

Phase III, Phase II Study Suberoylanilide Hydroxamic Acid (SAHA) Versus Placebo in Advanced Malignant Pleural Mesothelioma

Phase III, Phase II Study - Mesothelioma Avastin Plus Pemetrexed-Cisplatin Study

Phase III Study - Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer

Phase III - Electronic Tool to Record Cancer Symptoms in Patients With Advanced Cancer Receiving Palliative Care

Phase III Study - Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Phase III  Study - Fentanyl Sublingual Spray in Treating Cancer Patients With Breakthrough Pain

Phase I, Phase II Study - Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With MPM

Phase I, Phase II Study - A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma

Phase II Study - Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma

Phase II Study - Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence

Phase II Study - Pemetrexed Plus Cisplatin Neoadjuvant Therapy Followed By Surgery and Radiation in Mesothelioma

Phase II Study - AZD2171 in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

Phase II Study - A Phase II Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence

Phase II Study - Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

Phase II Study - Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

Phase II Study - Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen

Phase II Study - Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma

Phase II Study - Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma

Phase II Study - Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

Phase II Study - Surgery Plus IPHC to Treat Peritoneal Carcinomatosis

Phase II Study - Tomotherapy Treatment for Mesothelioma

Phase II Study - Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma

Phase II Study - Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

Phase II Study - Bortezomib in Treating Patients With Malignant Pleural Mesothelioma

Phase II Study - Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery

Phase II Study - A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma

Phase II Study - An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma

Phase II Study - Valproate and Doxorubicin in Malignant Mesothelioma

Phase II Study - An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma

Phase I Study - Decitabine and FR901228 in Treating Patients With Advanced Lung Cancer, Esophageal Cancer, Pleural Mesothelioma, or Lung Metastases

Phase I Study - FR901228 and Flavopiridol in Treating Patients With Advanced Lung, Esophageal, or Pleural Cancer

Phase I Study - Gene Therapy for Pleural Malignancies

Phase I Study - BMS-690514 in Patients With Advanced or Metastatic Solid Tumors

Phase I Study - Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma

Phase I Study - Cisplatin, Imatinib Mesylate, and Pemetrexed in Malignant Mesothelioma Patients

Phase I Study - Using Sunitinib Plus Radiation Therapy for Cancer Patients

Phase I Study - Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis

Phase I Study - A Study To Find the Best Dose of SU011248 When Given With Pemetrexed, Pemetrexed and Cisplatin Or Pemetrexed and Carboplatin in Patients With Advanced Solid Tumors

Phase I Study - Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma

Phase I Study - Immunotoxin Therapy, Pemetrexed, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed by Surgery

Phase I Study - Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment

Phase I Study - Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide

No Phase Specified - Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery

No Phase Specified - Biobank Sarcoma: Storing Blood for Analysis of DNA and Protein of Patients With Sarcoma

No Phase Specified - Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers

No Phase Specified - Study of Patients With Non-Small Cell Lung Cancer, Esophageal Cancer, or Malignant Pleural Mesothelioma

No Phase Specified - Multiple Biomarkers in Undiagnosed Pleural Effusion

No Phase Specified - Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite

No Phase Specified - Vibration Response Imaging (VRI) in Lung Cancer Patients

No Phase Specified - Mesothelin and Osteopontin as Diagnostic Markers in Patients With Mesothelioma or Atypical Mesothelial Hyperplasia

No Phase Specified - Study of Previously Collected and Stored Tissue Samples from Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial

No Phase Specified - Validation of a Novel Thoracic Neoplasm Radiotherapy Image Guidance Technique: A Pilot Study

No Phase Specified - The Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment Planning

No Phase Specified - Improving Functional Outcomes in Patients With Unilateral Vocal Cord Paralysis: Assessment of Adaptation Using Functional Magnetic Resonance Imaging

No Phase Specified - N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy

No Phase Specified - Correlation of x-Ray and Pathology With Needle Biopsy of Lung Tumors


    Simon, Eddins & Greenstone, LLP (C) 2009.
Created by WSI.
Sitemap | Privacy Statement | Terms of Use & Disclaimer | Contact | Login